vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
TriSalus Life Sciences, Inc. is the larger business by last-quarter revenue ($13.2M vs $8.6M, roughly 1.5× Affinity Bancshares, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs -73.9%, a 98.7% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs 12.8%). Affinity Bancshares, Inc. produced more free cash flow last quarter ($11.2M vs $-2.5M). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 8.1%).
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
AFBI vs TLSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $13.2M |
| Net Profit | $2.1M | $-9.8M |
| Gross Margin | — | 86.7% |
| Operating Margin | 35.9% | -24.8% |
| Net Margin | 24.9% | -73.9% |
| Revenue YoY | 12.8% | 59.8% |
| Net Profit YoY | 58.5% | 3.5% |
| EPS (diluted) | $0.34 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $13.2M | ||
| Q3 25 | $8.4M | $11.6M | ||
| Q2 25 | $8.3M | $11.2M | ||
| Q1 25 | $7.8M | $9.2M | ||
| Q4 24 | $7.6M | $8.3M | ||
| Q3 24 | $8.0M | $7.3M | ||
| Q2 24 | $8.3M | $7.4M | ||
| Q1 24 | $7.3M | $6.5M |
| Q4 25 | $2.1M | $-9.8M | ||
| Q3 25 | $2.2M | $-10.8M | ||
| Q2 25 | $2.2M | $-8.3M | ||
| Q1 25 | $1.8M | $-10.4M | ||
| Q4 24 | $1.3M | $-10.1M | ||
| Q3 24 | $1.7M | $-2.4M | ||
| Q2 24 | $1.0M | $-4.3M | ||
| Q1 24 | $1.3M | $-13.2M |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 83.5% | ||
| Q2 25 | — | 83.9% | ||
| Q1 25 | — | 83.7% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 86.3% | ||
| Q2 24 | — | 87.6% | ||
| Q1 24 | — | 85.0% |
| Q4 25 | 35.9% | -24.8% | ||
| Q3 25 | 34.9% | -77.9% | ||
| Q2 25 | 34.1% | -65.4% | ||
| Q1 25 | 30.8% | -79.9% | ||
| Q4 24 | 21.1% | -91.8% | ||
| Q3 24 | 28.5% | -118.9% | ||
| Q2 24 | 16.2% | -111.0% | ||
| Q1 24 | 24.0% | -180.8% |
| Q4 25 | 24.9% | -73.9% | ||
| Q3 25 | 26.5% | -93.5% | ||
| Q2 25 | 25.9% | -73.9% | ||
| Q1 25 | 23.4% | -113.2% | ||
| Q4 24 | 17.7% | -122.4% | ||
| Q3 24 | 21.7% | -32.6% | ||
| Q2 24 | 12.5% | -58.8% | ||
| Q1 24 | 18.2% | -204.5% |
| Q4 25 | $0.34 | $-0.22 | ||
| Q3 25 | $0.34 | $-0.96 | ||
| Q2 25 | $0.33 | $-0.27 | ||
| Q1 25 | $0.28 | $-0.39 | ||
| Q4 24 | $0.21 | $-0.38 | ||
| Q3 24 | $0.26 | $-0.12 | ||
| Q2 24 | $0.16 | $-0.21 | ||
| Q1 24 | $0.20 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $-33.9M |
| Total Assets | $881.7M | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | $20.4M | ||
| Q3 25 | $84.8M | $22.7M | ||
| Q2 25 | $89.7M | $26.5M | ||
| Q1 25 | $74.7M | $13.0M | ||
| Q4 24 | $41.4M | $8.5M | ||
| Q3 24 | $52.3M | $11.3M | ||
| Q2 24 | $50.4M | $16.5M | ||
| Q1 24 | $61.4M | $4.0M |
| Q4 25 | $127.0M | $-33.9M | ||
| Q3 25 | $125.4M | $-26.7M | ||
| Q2 25 | $124.1M | $-19.4M | ||
| Q1 25 | $122.3M | $-34.4M | ||
| Q4 24 | $129.1M | $-25.9M | ||
| Q3 24 | $128.4M | $-20.4M | ||
| Q2 24 | $125.1M | $-25.3M | ||
| Q1 24 | $123.3M | $-36.0M |
| Q4 25 | $881.7M | $35.3M | ||
| Q3 25 | $925.2M | $36.5M | ||
| Q2 25 | $933.8M | $41.3M | ||
| Q1 25 | $912.5M | $28.6M | ||
| Q4 24 | $866.8M | $24.0M | ||
| Q3 24 | $878.6M | $27.5M | ||
| Q2 24 | $873.6M | $32.4M | ||
| Q1 24 | $869.5M | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-2.5M |
| Free Cash FlowOCF − Capex | $11.2M | $-2.5M |
| FCF MarginFCF / Revenue | 130.9% | -19.1% |
| Capex IntensityCapex / Revenue | 4.9% | 0.3% |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-2.5M | ||
| Q3 25 | $3.7M | $-3.7M | ||
| Q2 25 | $3.8M | $-7.3M | ||
| Q1 25 | $1.9M | $-4.5M | ||
| Q4 24 | $6.8M | $-5.7M | ||
| Q3 24 | $4.1M | $-10.8M | ||
| Q2 24 | $619.0K | $-13.4M | ||
| Q1 24 | $1.2M | $-10.9M |
| Q4 25 | $11.2M | $-2.5M | ||
| Q3 25 | $3.6M | $-3.9M | ||
| Q2 25 | $3.7M | $-7.4M | ||
| Q1 25 | $1.8M | $-5.3M | ||
| Q4 24 | $6.4M | $-5.8M | ||
| Q3 24 | $4.0M | $-11.0M | ||
| Q2 24 | $489.0K | $-13.5M | ||
| Q1 24 | $1.1M | $-10.9M |
| Q4 25 | 130.9% | -19.1% | ||
| Q3 25 | 43.3% | -33.9% | ||
| Q2 25 | 44.0% | -66.1% | ||
| Q1 25 | 22.7% | -57.3% | ||
| Q4 24 | 83.9% | -69.7% | ||
| Q3 24 | 49.5% | -149.9% | ||
| Q2 24 | 5.9% | -183.1% | ||
| Q1 24 | 14.8% | -169.3% |
| Q4 25 | 4.9% | 0.3% | ||
| Q3 25 | 0.8% | 1.9% | ||
| Q2 25 | 1.4% | 0.8% | ||
| Q1 25 | 1.9% | 8.2% | ||
| Q4 24 | 5.6% | 0.6% | ||
| Q3 24 | 1.7% | 2.3% | ||
| Q2 24 | 1.6% | 0.8% | ||
| Q1 24 | 1.8% | 1.0% |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
